Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.59 |
| ▸ | CTSS | P25774 | 4/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3842588 | 1.00 | CTSK (0.59) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL7696221 | 1.00 | CTSK (0.59) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL7729227 | 0.95 | CTSK (0.55) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL7375068 | 0.95 | CTSK (0.55) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL13198524 | 0.92 | ATM (0.55) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL7375856 | 0.91 | CTSK (0.51) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL25842742 | 0.89 | CTSK (0.54) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL21715604 | 0.88 | CTSK (0.56) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL18653949 | 0.88 | CTSK (0.58) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL4727222 | 0.88 | CTSK (0.58) | CTSKCTSSATMSYKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365207-B2 | Sulfur-containing polycyclic-hydroxypyridone carboxamide analog against HIV | MO, Yunfen (CN) | 2022-06-21 | — | — | US | disclosed |
| CN-112867706-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20200361960-A1 | SULFUR-CONTAINING POLYCYCLIC-HYDROXYPYRIDONE CARBOXAMIDE ANALOG AGAINST HIV | MO, Yunfen | 2020-11-19 | — | — | US | disclosed |
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| EP-2475428-B1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2015-07-01 | — | — | EP | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| US-8486940-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-07-16 | — | — | US | disclosed |
| US-7309721-B2 | Immunosuppressants for treating diseases and conditions of bone marrow, organ and tissue transplant rejection; chemotherapeutic drug for cancers; antiinflammatory agents for rheumatoid arthritis; activate the production of lymphocyte; 2-Amino-4-(4-(octylphenyl))butanol, O-phosphate | MERCK + CO., INC. (US) | 2007-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365207-B2 | Sulfur-containing polycyclic-hydroxypyridone carboxamide analog against HIV | TBK1, TYMP, TST | CTSK 3958/4885CTSS 2337/4885ATM 3401/4885 |
| US-20200361960-A1 | SULFUR-CONTAINING POLYCYCLIC-HYDROXYPYRIDONE CARBOXAMIDE ANALOG AGAINST HIV | TYMP, MAVS, DHPS | CTSK 3544/4885CTSS 1850/4885ATM 3637/4885 |
| US-20140065095-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | CTSK 2891/4885CTSS 2246/4885ATM 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.